Company: TVRD
Filing Date: 2025-05-13
Form Type: 8-K
Source: 0001104659-25-047856
Chunk: 5

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-05-13
Form: 8-K
Item: Item 9.01
Chunk 5
---
Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

  Exhibit No.      Description                                                                   
         16.1      Letter from Ernst & Young LLP to the SEC dated May 13, 2025.                  
         99.1      Press release issued on May 13, 2025.                                         
 ─────────────────────────────────────────────────────────────────────────────────────────────────
          104      Cover Page Interactive Data File (embedded within the Inline XBRL document).  

SIGNATURES

Pursuant to the requirements
of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.

                          TVARDI THERAPEUTICS, INC.                               
  Date: May 13, 2025      By:                            /s/ Imran Alibhai        
                          Name:                          Imran Alibhai            
                          Title:                         Chief Executive Officer